ASLN:NSD-ASLAN Pharmaceuticals Limited (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.90

Change

-0.41 (-9.51)%

Market Cap

USD 0.25B

Volume

9.12M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore. Address: 83 Clemenceau Avenue, Singapore, Singapore, 239920

Company Website : http://aslanpharma.com

Address : 83 Clemenceau Avenue, Singapore, Singapore, 239920

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.42

52 Week High : 6.75

Short Ratio : 0.02

52 Week Low : 0.83

Shorted Shares : 16,643

200 Day Moving Average : 2.08

Shorted Shares Previous Month : 12,753

50 Day Moving Average : 3.03

Shares Held by Institutions : 10.72%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-15.59 (-10.62%)

 USD58.69B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-3.62 (-1.71%)

 USD55.13B 20.61 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.13 (-1.79%)

 USD48.73B 14.90 11.87
ALXN Alexion Pharmaceuticals, Inc

-2.18 (-1.45%)

 USD33.27B 55.63 33.22
BGNE BeiGene, Ltd

-1.91 (-0.62%)

 USD29.03B N/A N/A
RPRX Royalty Pharma plc

-3.38 (-7.20%)

 USD28.50B 22.60 14.17
SGEN Seagen Inc

-5.78 (-3.76%)

 USD27.85B 45.61 37.70
BNTX BioNTech SE

-7.73 (-7.36%)

 USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.28 (-3.78%)

 USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ASLN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 113.11% 96% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 113.11% 96% A 96% A
Trailing 12 Months  
Capital Gain 98.98% 76% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 98.98% 76% C 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.96% 13% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.96% 13% F 6% F
Risk Return Profile  
Volatility (Standard Deviation) 45.10% 63% D 31% F
Risk Adjusted Return -48.68% 17% F 12% F
Market Capitalization 0.25B 38% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.10 82% B- 91% A-
Price/Book Ratio 6.05 47% F 31% F
Price / Cash Flow Ratio -0.31 11% F 56% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -5,313.82% 1% F 0% N/A
Return on Invested Capital -115.92% 20% F 8% F
Return on Assets -49.34% 15% F 5% F
Debt to Equity Ratio -1,051.15% 99% A+ 99% A+
Technical Ratios  
Short Ratio 0.02 99% A+ 98% A+
Short Percent N/A N/A N/A N/A N/A
Beta 2.42 11% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector